Sichuan Kelun Pharmaceutical Co., Ltd. (SHE:002422)
42.29
-0.02 (-0.05%)
Nov 18, 2026, 3:00 PM CST
SHE:002422 Revenue
Sichuan Kelun Pharmaceutical had revenue of 4.27B CNY in the quarter ending September 30, 2026, with 1.93% growth. This brings the company's total for the last twelve months to 18.35B, up 0.27% year-over-year. In the year 2025, Sichuan Kelun Pharmaceutical had annual revenue of 18.51B, down -15.13%. That makes Sichuan Kelun Pharmaceutical the 4,052nd largest company in the world by revenue and 520th in China.
Revenue (ttm)
18.35B
Revenue Growth
+0.27%
P/S Ratio
3.67
Revenue / Employee
911.66K
Employees
20,127
Market Cap
67.26B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full SHE:002422 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 18.51B | -3.30B | -15.13% |
| Dec 31, 2024 | 21.81B | 358.49M | 1.67% |
| Dec 31, 2023 | 21.45B | 2.42B | 12.69% |
| Jan 1, 2023 | 19.04B | 1.76B | 10.19% |
| Jan 1, 2022 | 17.28B | 813.21M | 4.94% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
Revenue RankingsSichuan Kelun Pharmaceutical News
- 2 months ago - Sichuan Kelun Pharmaceutical Quarterly report: H1 2026 - Filings
- 2 months ago - Sichuan Kelun Pharmaceutical Slides: H1 2026 - Filings
- 6 months ago - Sichuan Kelun Pharmaceutical Quarterly report: Q1 2026 - Filings
- 7 months ago - Sichuan Kelun Pharmaceutical Earnings Call Transcript: H2 2025 - Transcripts
- 7 months ago - Sichuan Kelun Pharmaceutical Annual report: H2 2025 - Filings
- 10 months ago - Sichuan Kelun Pharmaceutical Transcript: 44th Annual J.P. Morgan Healthcare Conference - Transcripts
- 11 months ago - Crescent, Kelun-Biotech Sign Oncology Deal; Crescent To Raise $185 Mln; Stock Up - Nasdaq